FY2026 Third Quarter Financial Briefing Materials
Filed with TSE · · 21 pages · English
Summary by 6ix AI
The report highlights ongoing progress in proprietary drug development and commercialization efforts, particularly for the Perfusio® system. It also notes a revision to the full-year earnings forecast due to changes in joint research plans, resulting in an expected increase in net loss. Overall, the company is focused on expanding its RNA-targeted drug pipeline and securing new contracts to enhance its revenue base.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Earlier from Veritas In Silico
- Monthly Status of Exercise of #5 (with Exercise Price Adjustment Clause) and #6 to #9 Share Acquisition Rights(with Target Issue and Adjustment Optio
- Syntara and Veritas In Silico sign MoU to Accelerate Joint Discovery Research for mRNA-Targeted Compounds
- Notice of Completion of Payment for #5 and #6 to #9 Share Acquisition Rights by Third-Party Allotment
- Notice Concerning Achievement of Research Milestone under Joint Drug Discovery with Toray Industries, Inc.
- Non-consolidated Financial Results for the Six Months Ended June 30, 2026 [Under Japanese GAAP]
Follow Veritas In Silico into a list and get an email when it puts out news.
Follow Veritas In Silico